This 66% move wasn’t random

The strange dynamic when companies dip under a dollar

February 19, 2026

Issuer-Sponsored Content from bioAffinity Technologies, Inc*

I’ve been watching something interesting play out with a small Nasdaq stock that just battled its way back above the key $1 level. Solid news and revenue growth have helped this one snap back strong. It’s well worth a closer look today.

TODAY’S TOP ALERT! 

bioAffinity Technologies (Nasdaq: BIAF)

👉BIAF is TODAY’S #1 ALERT*👈

Good morning, Folks, Jeff Bishop here,

If you’ve followed my dispatches for a while, you know one theme I always hammer on is how Nasdaq-listed companies will fight like heck to keep their stock prices above $1.00.

That’s because of the Nasdaq’s minimum bid price rule, which declares a company noncompliant if its stock closes below $1.00 for 30 consecutive business days.

With that in mind, take a close look at my “tactical trade” idea of the day: bioAffinity Technologies, Inc. (BIAF)*.

You can see the stock took a dip below $1.00 on February 4. It hit a bottom the next day and has made a very convincing 66% bounce over the last two weeks.

It’s now back above the $1.00 threshold at $1.15, and recent press releases (details below) may be enough to keep it powering higher.

I’m watching it closely for another leg up today.

👉BIAF is TODAY’S #1 ALERT*👈

1. Noninvasive lung cancer test 🧪

bioAffinity’s flagship product, CyPath® Lung, is a noninvasive diagnostic test that helps doctors decide if suspicious lung nodules are cancerous by analyzing sputum samples.

This matters because lung cancer is by far the deadliest cancer, and earlier detection typically saves lives.

The goal is to have a smarter first line of defense before expensive biopsies or surgeries.

2. Strong clinical performance 📈

The company has consistently released new case studies showing that CyPath® Lung can inform real-world clinical decisions, including avoiding unnecessary procedures and detecting early-stage cancers people otherwise might miss.

A press release from Tuesday highlighted a case where the test gave both doctor and patient confidence to stick with surveillance rather than invasive options.

3. Heavyweight medical experts backing the science 🩺 

On February 9, bioAffinity announced the appointment of nationally recognized lung and pulmonary specialists to its Medical & Scientific Advisory Board. 

These are names from top institutions such as MD Anderson, NYU Langone and Wisconsin School of Medicine — experts who bring credibility and influence as CyPath® Lung pushes into broader adoption.

4. Growing commercial momentum 📊

In its Q3 2025 financial results, BIAF reported that CyPath® Lung revenues increased 86% year over year for the first nine months of 2025, “driven by higher test volumes and growing clinical adoption, including the Veterans Administration (VA).”

It added that CyPath® Lung sales reached “a record high in the third quarter of 2025, representing a 92% increase over the previous quarter.”

5. 🌐 Accreditation & Visibility in Key Forums

CyPath® Lung’s lab operations maintain prestigious accreditation from the College of American Pathologists (CAP) — an important mark of clinical quality. 

In addition, in December BIAF revealed that the test has been selected to be highlighted at the American Cancer Society’s National Lung Cancer Roundtable.

Between accreditation and national awareness, this helps build credibility with clinicians and payers.

Final Thoughts

What sets bioAffinity apart from many early-stage biotech peers is that it already has:

  • A commercial product with demonstrated clinical utility,

  • Growing real-world usage,

  • Expert medical backing, and

  • Visibility in respected medical forums.

That’s unlike many biotechs that are years away from even human trials. CyPath® Lung is already being ordered by physicians and supported with case studies — which is rare for a micro-cap in this space.

For a deeper dive, be sure to check out the company’s website, especially this page with videos about how the test works.

As always, be sure to approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. 

Please read the full disclaimer at the bottom of this email as well so you are aware of our compensation and other conflicts of interest, as well as additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

Bottom line: BIAF ricocheted off its bottom two weeks ago and is now up 66%.

With record revenues and solid recent press releases, I’m watching closely to see if the momentum continues from here.

Tune into BIAF to find out!

To Your Success,

*ISSUER-SPONSORED DISCLAIMER: This entity is owned by Sherwood Ventures LLC (SV). To more fully understand any SV subscription, website, application or other service, please review our full disclaimer located at https://bullseyealerts.com/disclaimer/

Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call “typical.”

Just a quick heads up about this ad you're reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received twenty five thousand dollars (cash) from bioAffinity Technologies, Inc (via Sica Media) for a one day marketing program starting on February 19, 2026.

It might seem obvious, but while our client claims not to own any shares in bioAffinity Technologies, Inc, whoever ultimately paid them most likely owns shares. You should assume they are looking to sell some or all of them at any time after we send out this information, which might negatively affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither Sherwood Ventures nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as the marketing campaign ends, though that is not always the case.

Now, diving right into bioAffinity Technologies, Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies who are paying us and we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, neither Sherwood Ventures nor its owners, employees, or independent contractors are registered as a securities broker-dealer, broker, 1nvest.ment advis0r (IA), or IA rep’s with the SEC, any state securities regulatory authority, or any self-regu1atory organization.

So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture.